NDA 205579 · Eagle Pharms
Ryanodex
Dantrolene Sodium · Intravenous
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jul 22, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 1 recruiting
FAERS reports
410
346 serious, 47 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2024.
RYANODEX ® is indicated for the: Treatment of malignant hyperthermia in conjunction with appropriate supportive measures [see Dosage and Administration ( 2.1 )] Prevention of malignant hyperthermia in patients at high risk. RYANODEX is a skeletal muscle relaxant drug indicated for: Treatment of malignant hyperthermia in conjunction with appropriate supportive measures. ( 1 ) Prevention of malignant hyperthermia in patients at high risk. ( 1 )
Mechanism: In isolated nerve-muscle preparation, dantrolene has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca ++ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In affected humans, it has been postulated that “triggering agents” (e.g., general anesthetics and depolarizing neuromuscular...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 22, 2014 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelReviewSummary Review
1 products under this application
- RYANODEX · DANTROLENE SODIUM 250MG/VIAL · FOR SUSPENSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03109288 · 250 participants (planned) · Start Aug 11, 2017 · Primary completion Jan 1, 2027
Drug: Cilostazol; Leucovorin and 3 more · For: Multiple Sclerosis
Sites: Bethesda, Maryland
- The Use of Dantrolene to Improve Analgesia in Posterior Lumbar SurgeryPivotal-lookingCompleted
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT03762109 · 116 participants · Start Jul 29, 2019 · Primary completion Jun 1, 2024
Drug: Dantrolene; Placebo Oral Tablet · For: Lumbar Spine Injury
Sites: Boston, Massachusetts
- A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT04134845 · 68 participants · Start Aug 21, 2020 · Primary completion May 29, 2025
Drug: Dantrolene/Ryanodex; Placebo · For: Ventricular Tachycardia
Sites: Nashville, Tennessee
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01950520 · 47 participants · Start Feb 7, 2014 · Primary completion Dec 17, 2022
Drug: Propranolol; Pindolol and 11 more · For: Healthy Volunteers
Sites: Bethesda, Maryland
- Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)Pivotal-lookingTerminated
Medical University of ViennaAcademic, hospital or other
NCT00796900 · 34 participants (planned) · Start May 2008 · Primary completion Mar 2011
Drug: Dantrolene; Placebo · For: Hyperthermia
Sites: Vienna, Austria
Eagle Pharmaceuticals, Inc.Industry
NCT02513095 · 34 participants · Start Sep 2015 · Primary completion Sep 2015
Drug: Dantrolene sodium for injectable suspension · For: Heat Stroke
Sites: Mecca, Saudi Arabia
University of Massachusetts, WorcesterAcademic, hospital or other
NCT01024972 · 31 participants · Start Oct 2009 · Primary completion Jul 2013
Drug: Dantrolene; Placebo · For: Subarachnoid Hemorrhage; Cerebral Vasospasm
Sites: Worcester, Massachusetts
- Dantrolene in Statin-induced MyopathyPivotal-lookingNot yet recruiting
Tanta UniversityAcademic, hospital or other
NCT06966843 · 23 participants (planned) · Start Oct 2027 · Primary completion Jan 2029
Drug: Dantrolene; Placebo · For: Statins Induced Myopathy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neuroleptic malignant syndrome44
- respiratory failure35
- drug ineffective31
- muscular weakness29
- asthenia28
- pyrexia28
- convulsion26
- diarrhoea26
- vomiting21
- fatigue19
- off label use19
- pneumonia19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 9 |
| 2006 | 18 |
| 2007 | 28 |
| 2008 | 29 |
| 2009 | 27 |
| 2010 | 15 |
| 2011 | 37 |
| 2012 | 16 |
| 2013 | 10 |
| 2014 | 11 |
| 2015 | 8 |
| 2016 | 19 |
| 2017 | 18 |
| 2018 | 23 |
| 2019 | 19 |
| 2020 | 21 |
| 2021 | 16 |
| 2022 | 18 |
| 2023 | 24 |
| 2024 | 13 |
| 2025 | 16 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2001 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Young CA, Boggild M · Cochrane Database Syst Rev 2000 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2003 · Systematic Review
- Myoplasmic Ca2+ concentration during exertional rhabdomyolysis.
López JR, Rojas B, Gonzalez MA, et al. · Lancet 1995 · Clinical Trial, Controlled Clinical Trial
- Calcium antagonists for Duchenne muscular dystrophy.
Phillips MF, Quinlivan R · Cochrane Database Syst Rev 2008 · Systematic Review
Sponsor: Eagle Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.